Skip to main content

Table 2 Array CGH results (n = 31) in ESFT patient samples arranged by diagnosis.

From: Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors

Code Diagnosis Origin of sample Array CGH results Number of changes CDKN2A
deletion status1
D150 Ewing PRI +1q, +2, +4, +6, +7, +8, -10, +12, -16q, +17, -19, +20 12 No deletion 2
D152 Ewing PRI +5, +7, +8, +21 4 No deletion 2
D153 Ewing PRI +1, -2q35-qter, +6, +8, +9p, -9q34.11, -10, +11q24.3-qter, +12, +16p, +19, +20q12-qter, +22q11.21-q12.1 13 No deletion 2
D154 Ewing PRI -3p13, -3p25.1-p25.3, -6q21, -6q24.1-q24.2, +8p11.21-p21.2, -8p21.3-pter, +8q, -9q, amp20q11.23, -20q11.23-q13.12, amp20q13.12-q13.2, +20q13.2-qter, -22q11.23, amp22q12.1-q12.1 (uncontinuous), +22q12.2-q12.3, -22q12.3-qter 16 No deletion 2
D155 Ewing PRI No changes detected 0 No deletion 2
D162 Ewing PRI -9p21.2-p21.3 1 Heterozygous deletion 2
D239 Ewing PRI No changes detected 0 No deletion 2
D240 Ewing PRI +1q22-qter, +12, +Xq26.3-qter 3 No deletion 2
D241 Ewing PRI No changes detected 0 No deletion 2
D245 Ewing PRI +4q25-qter, +5, +8, +13q11-q12.2 4 No deletion 2
D248 Ewing PRI +1, +2q21.2-q33.1, amp 2q31.2-q33.1, -2q33.2-qter, -4, +8, del 9p21.3, -10, +11q24.3-qter, +12, +14, -16p12.3, -16q, +17p, -17q, +22q11.21-q12.1 16 Homozygous deletion 2
D250 Ewing PRI -3q13.31-q22.3, del 9p21.3, -Xp11.3 3 Homozygous deletion 2
D311 Ewing PRI +1q22-qter, +8, -10p15.3, -16q, +17q21.31-qter, -19q13.43 6 No deletion 3
D313 Ewing PRI +2, +8 2 No deletion 3
D316 Ewing PRI +2, +8, +14q11.2-q13.2, -14q13.3-q21.1, +14q21.1-qter, -X 6 No deletion 3
D320 Ewing PRI +8 1 No deletion 3
D322 Ewing PRI +8, -16q, +19p 3 No deletion 3
D242 Ewing Extr PRI +1q 1 No deletion 2
D246 Ewing Extr PRI No changes detected 0 No deletion 2
D249 Ewing Extr PRI -1p34.3-pter, +3p22.1-pter, -6p11.2-p21.31, +8, -10q23.1, +10q25.1-qter, -13q13.3-q14.3, +13q21.1-q22.1, +15q21.3-q22.2, +19q13.31-qter, +20q13.33 11 No deletion 2
D252 Ewing Extr PRI +2, +5, +6, -7, +8, -9p21.3, +12, +14, +21, -X 10 Homozygous deletion 2
D253 Askin's PRI +8, -Y 2 No deletion 2
D254 Askin's PRI +2, +3, -4q34.3-qter, -5, +6, -7, -9, del 9p21.3, -10, +11q24.3-qter, +12, -13, +14, +16, +18, +19, +20, +21, +22q11.21-q12.1 19 Homozygous deletion 2
D157 Ewing REC +2p, +2q11.2-q22.3, -3q13.13-q13.33, +4q31.3-qter, +8, +12p, +12q12-q21.31, -16q, -17p, -19, +X 11 No deletion 2
D156 Askin's REC +1q, +8p11.21-p11.22, +8p23.1-pter, +8q, +11q12.3-q13.2, +12q13.2-q14.1, -16q, +19p 8 No deletion 2
D255 Ewing MET +1q, +2, +5, +6, +8, +12, +13, +15, -16, -17, +18, -19, +20, +21 14 No deletion 2
D256 Ewing MET -1q24.2-q25.3, +8 2 No deletion 3
D312 Ewing MET +1, +2p, +2q11.2-q21.3, -3, -4, -5q, +6p, +6q12, -6q13-qter, +7q, +8, +9, -10, -11p, -11q12.1-q24.2, +11q24.3-qter, +12, -13, +14, +15q15.2-qter, -16q, -17, -18, -19, +20, +X 26 No deletion 3
D321 Ewing MET +2, +5, +6, +8, +14, +15, -16q, -20p, +21, -Xp11.21-p11.22, -Xq 11 No deletion 3
D257 PNET MET +1p11.2-p13.2, +1p22.1-p32.3, +1p35.1-pter, +1q, -3p24.3-p25.1, +6q23.1-qter, +7, +8q, -9p, +9q22.1-q33.3, +12p, +12q12-q15 12 Heterozygous deletion 2
D315 PNET MET -7p, -9p21.1-p21.3, del 9p21.3, -16q, -22q12.1, -22q13.2-q13.32 6 Homozygous deletion 3
  1. 1 CDKN2A deletion was regarded as homozygous if the copy number log2 ratio was < -2.0 and as heterozygous if the ratio was -1.5 to -2.0. 2 CDKN2A deletion result published previously by Savola et al. [18] in an article, which included total of 26 ESFT patient samples. 3 CDKN2A deletion status not published before.
  2. Extr = extraskeletal; PRI = primary tumor; REC = local recurrence; MET = metastasis.